Mount Sinai researchers have identified genetic and cellular mechanisms of Crohn's disease, providing new insights for future treatments that could offer a tailored approach to patients with the chronic inflammatory disease, according to a study published in Nature on March 31.
The researchers found that blocking the common cytokine receptor subunit gp130 may benefit some patients with Crohn's disease and could complement a standard treatment for moderate to severe Crohn's disease known as anti-tumor necrosis factor (TNF) treatment. This treatment uses medications known as TNF inhibitors to block white blood cells producing the protein TNF, which causes the inflammation.
Crohn's disease is a chronic inflammatory intestinal disease with frequent abnormal healing and complications that narrow or constrict passage through the digestive tract. Complications associated with Crohn's disease are driven by communication between cells called macrophages that detect and destroy harmful bacteria or organisms, and cells known as fibroblasts that aid with wound healing. Mount Sinai researchers analyzed inflamed and normal tissues of the small intestine in humans, and zebrafish models of intestinal injury, and showed that a dysregulated macrophage-fibroblast niche can be driven by Crohn's disease-associated mutations in the gene NOD2.
These findings are reported on the 20th anniversary of the discovery by Judy H. Cho, MD, Dean of Translational Genetics and Director of The Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, her colleagues, and others that genetic variants that cause the protein produced by NOD2 to lose function are associated with increased risk for Crohn's disease. NOD2 recognizes bacterial components, and the intestinal immune system is exposed to high bacterial concentrations in both healthy and diseased states. However, the reasons why mutations in NOD2 cause increased risk for Crohn's disease and why some patients do not respond to anti-TNF medications remained incompletely defined until now. Patients carrying NOD2 mutations have increased activated fibroblast and macrophage gene expression, and in particular, elevated gp130-related gene expression. Given this finding, the researchers believe that blocking the protein gp130 may help patients who are nonresponsive to the treatment of anti-TNF medications.
"Our work defines a completely new mechanism whereby NOD2 mutations confer risk, namely through altered differentiation of newly recruited blood monocytes over time," says Dr. Cho. "It sharpens current research efforts involved in serial tissue and blood analyses to define how non-response or loss-of-response to anti-TNF therapies may be improved."
Shikha Nayar, the study's first author and a PhD candidate in Dr. Cho's lab at Icahn Mount Sinai, said the findings could provide a more custom-made approach to future patient care. "We've developed novel in vivo and in vitro models to define mechanisms and timing of disease progression," she says. "These studies may help tailor treatments more effectively for Crohn's disease patients carrying NOD2 mutations and elevated signatures we have described."
The Department of Pediatric Gastroenterology at Emory University contributed to the study. This work was also supported by National Institutes of Health (NIH) grants R01 DK106593, R01 DK123758-01, U01 DK062422 (to J.H.C.).
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care--from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
For more information, visit https:/